Affinium Pharmaceuticals, Ltd. Announces the Initiation of a Phase I ClinicalTrial Using an Oral Formulation of AFN-1252
Affinium Pharmaceuticals announced the commencement of a Phase I study in the United States for its novel molecular entity, AFN-1252, a first in class antibiotic candidate focused on the oral and IV treatment of susceptible and highly resistant strains of Staphylococcus aureus (MRSA). The study will evaluate the safety and tolerability of a new, oral tablet formulation.
Dr. Barry Hafkin, Chief Medical Officer of Affinium Pharmaceuticals, noted, "We have previously documented good oral bioavailability and excellent tolerability of the drug candidate in two previous clinical studies using simple oral formulations, and we are very pleased to move a newly developed oral formulation that we expect will optimize the pharmacokinetic profile of AFN-1252. We anticipate that the trial will be completed in the third quarter of this year, and that AFN-1252 will continue to demonstrate the excellent tolerability and safety seen in previous studies."
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Sigma-Aldrich Announces Service Provider for Whole Genome Amplification Technology

Smartphone lab finds coronavirus in saliva - Diagnosis of other infectious diseases possible
Affimed Appoints Dr. Wolfgang Fischer as Chief Operating Officer
S*BIO Announces US$5 Million Investment by Mitsui Ventures

Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”

Fujifilm to Invest Over 200 Billion yen to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A. - End-to-End Single-Site Solution from Drug Substances to Fill-Finish & Packaging
Researchers discover that DNA naturally fluoresces
